Skip to main content

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

The Company to host an earnings conference call via webcast

MindWalk Holdings Corp. (NASDAQ: HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will report financial results for the third quarter of fiscal year 2026 and host a conference call on Thursday, March 12, 2026, at 10:30 AM Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session.

Conference Call and Webcast Details

The live webcast will take place on Thursday, March 12, 2026, at 10:30AM ET.

The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at:

https://ir.mindwalkai.com/events-and-presentations/default.aspx

* Webcast Details *
Event Title: MindWalk Holdings Corp. – Third Quarter Fiscal Year 2026 Financial Results
Event Date: March 12, 2026, 10:30 AM (GMT-04:00) Eastern Time (US and Canada)

Attendee URL: https://events.q4inc.com/attendee/486881652

Participant Dial-in:
USA / International Toll +1 (646) 307-1963
USA - Toll-Free (800) 715-9871
Canada - Toronto (647) 932-3411
Canada - Toll-Free (800) 715-9871
Conference ID: 3224490

Anyone listening to the call is encouraged to read the company’s periodic reports available on the company’s profile at www.sedarplus.ca and www.sec.gov, including the discussion of risk factors and historical results of operations and financial condition in those reports.

About MindWalk
MindWalk is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT® technology and the LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.50
+0.00 (0.00%)
AAPL  266.43
+0.00 (0.00%)
AMD  258.12
+0.00 (0.00%)
BAC  54.32
+0.00 (0.00%)
GOOG  334.47
+0.00 (0.00%)
META  671.58
+0.00 (0.00%)
MSFT  411.22
+0.00 (0.00%)
NVDA  198.86
-0.01 (-0.01%)
ORCL  169.81
+0.00 (0.00%)
TSLA  391.95
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.